AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31587812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (exact dosage and duration not specified)
Number of subjects: 41
Study 31587812 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring ketones (part of the intervention process)
Number of subjects: 41
Study 27941020 — intervention group
Group type: EXPERIMENTAL
Intervention: SonR contractility sensor-guided optimization
Number of subjects: 998
Study 27941020 — intervention group
Group type: COMPARATOR
Intervention: Echo-guided optimization
Number of subjects: 998
Study 25070348 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 9
Study 25070348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22991267 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate 60 mmol/d
Number of subjects: 52
Study 22991267 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate 90 mmol/d
Number of subjects: 52
Study 22991267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21788629 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 531
Study 18832600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar diskectomy
Number of subjects: 1000
Study 18832600 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 1000
Study 16950468 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane echocardiography
Number of subjects: 50
Study 16950468 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane-guided 3D echocardiography
Number of subjects: 50
Study 16950468 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2D dobutamine stress echocardiography
Number of subjects: 50
Study 14515062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 34
Study 14515062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10972601 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 20
Study 10972601 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 20
Study 7494563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m²) + Paclitaxel (135 mg/m² over 24 hours)
Number of subjects: 410
Study 7494563 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m²) + Cyclophosphamide (750 mg/m²)
Number of subjects: 410
Study 7494563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Paclitaxel
Number of subjects: 410
Study 7494563 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + Cyclophosphamide
Number of subjects: 410
Study 1527459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin-metronidazole protocol for 10 days
Number of subjects: 122
Study 1527459 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, gentamicin, cephalexin and metronidazole (various combinations for 5 or 10 days)
Number of subjects: 122
Study 3893039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g acetylsalicylic acid (ASA) for two days
Number of subjects: 25
Study 3893039 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two days
Number of subjects: 25
Study 31805012 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30
Study 31805012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30
Study 31805012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg NAC BID for 12 weeks then TID for 12 weeks
Number of subjects: 30
Study 30376082 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 966
Study 30376082 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of IPV doses
Number of subjects: 966
Study 30376082 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic levels
Number of subjects: 966
Study 27261982 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion plus rehabilitation training (MRT group, n=44)
Number of subjects: 84
Study 27261982 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (RT group, n=40)
Number of subjects: 84
Study 27261982 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion plus rehabilitation training (MRT group)
Number of subjects: 84
Study 27261982 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (RT group)
Number of subjects: 84
Study 24856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial monitoring
Number of subjects: 60
Study 24856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 60
Study 24856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stake in conformity
Number of subjects: 60
Study 24856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal factors
Number of subjects: 60
Study 22633184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-titration group
Number of subjects: 60
Study 22633184 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-titration group
Number of subjects: 60
Study 22633184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20977036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 0
Study 20977036 — intervention group
Group type: COMPARATOR
Intervention: Hassles condition
Number of subjects: 0
Study 20977036 — intervention group
Group type: EXPERIMENTAL
Intervention: Any event condition
Number of subjects: 0
Study 18164168 — intervention group
Group type: EXPERIMENTAL
Intervention: Debiasing technique (participants listing advantages and disadvantages of each treatment)
Number of subjects: 102
Study 18164168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no debiasing technique)
Number of subjects: 102
Study 16289799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine subjects with anxiety alone
Number of subjects: 1957
Study 16289799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine subjects with depression alone
Number of subjects: 1957
Study 16289799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine subjects with both anxiety and depression
Number of subjects: 1957
Study 16289799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active migraine subjects with neither anxiety nor depression
Number of subjects: 1957
Study 16289799 — intervention group
Group type: COMPARATOR
Intervention: Non-migraine subjects
Number of subjects: 1957
Study 12118746 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bonded extracorporeal circuits (group H)
Number of subjects: 40
Study 12118746 — intervention group
Group type: COMPARATOR
Intervention: Plain extracorporeal circuits (group C)
Number of subjects: 40
Study 12118746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group H and group C)
Number of subjects: 40
Study 10094133 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin 2A receptor variant (102T/C) in schizophrenic patients
Number of subjects: 97
Study 10094133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment in schizophrenic patients
Number of subjects: 97
Study 10094133 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 97
Study 7747231 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method of treatment
Number of subjects: 89
Study 7747231 — intervention group
Group type: COMPARATOR
Intervention: Patient education in mini back school
Number of subjects: 89
Study 2103969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-glucuronilglucosaminoglycane treatment
Number of subjects: 0
Study 2103969 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7408684 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol (Prent)
Number of subjects: 20
Study 7408684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31238304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Number of subjects: 60
Study 31238304 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (sit-to-stand exercise without HAL)
Number of subjects: 60
Study 28697113 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with 18 mL 1% lidocaine and 2 mL sodium bicarbonate
Number of subjects: 41
Study 28697113 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 41
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 73
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical activity
Number of subjects: 73
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity
Number of subjects: 73
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral forefoot pressure
Number of subjects: 73
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral midfoot pressure
Number of subjects: 73
Study 24905767 — intervention group
Group type: EXPERIMENTAL
Intervention: Second toe pressure
Number of subjects: 73
Study 23463624 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and oral cyclophosphamide (CCy)
Number of subjects: 82
Study 23463624 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 82
Study 20813884 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg plus fluticasone propionate 500 μg, twice a day
Number of subjects: 5112
Study 19481079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EVL, propranolol (dose titrated to reduce heart rate to 55 bpm), and ISMN (40 mg/day)
Number of subjects: 177
Study 19481079 — intervention group
Group type: COMPARATOR
Intervention: EVL alone
Number of subjects: 177
Study 19481079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EVL, propranolol, and ISMN
Number of subjects: 177
Study 19481079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients in combination group
Number of subjects: 177
Study 19481079 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients in EVL alone group
Number of subjects: 177
Study 15783243 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran
Number of subjects: 6948
Study 15783243 — intervention group
Group type: COMPARATOR
Intervention: comparator
Number of subjects: 6948
Study 11916195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine gel (200 mg)
Number of subjects: 19
Study 11916195 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 19
Study 11916195 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 19
Study 10414879 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (9MU/d) + zidovudine (2x250 mg/d)
Number of subjects: 26
Study 10414879 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (15 mg every 2 weeks) + zidovudine (2x250 mg/d)
Number of subjects: 26
Study 8643806 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling plus adventure experiences
Number of subjects: 84
Study 8643806 — intervention group
Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 84
Study 8643806 — intervention group
Group type: COMPARATOR
Intervention: adventure only
Number of subjects: 84
Study 8643806 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 84
Study 2205572 — intervention group
Group type: EXPERIMENTAL
Intervention: Early arthroscopy (within 48 h)
Number of subjects: 82
Study 2205572 — intervention group
Group type: COMPARATOR
Intervention: Delayed arthroscopy (3 to 21 days after the injury)
Number of subjects: 82
Study 2205572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 6778187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (750 mg i.v. during a 15-minute period followed by 800 mg orally and later 400 mg t.i.d.)
Number of subjects: 112
Study 6778187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 29941389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial lubricant (n=385)
Number of subjects: 1000
Study 29941389 — intervention group
Group type: COMPARATOR
Intervention: Standard lubricant (control group, n=347)
Number of subjects: 1000
Study 28931991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretching
Number of subjects: 22
Study 28931991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve mobilization
Number of subjects: 22
Study 25645168 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 54
Study 25645168 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment waitlist control group
Number of subjects: 54
Study 24025143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ornithine aspartate plus naloxone
Number of subjects: 84
Study 24025143 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical treatment
Number of subjects: 84
Study 21429443 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg/1 ml
Number of subjects: 250
Study 21429443 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 75 mg/3 ml
Number of subjects: 250
Study 18771676 — intervention group
Group type: EXPERIMENTAL
Intervention: Random number generation (RNG) of digits from 1 to 6
Number of subjects: 19
Study 18771676 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 19
Study 17161227 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber (Konjac-mannan, 3g/d)
Number of subjects: 30
Study 17161227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17161227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 15213041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1000 IU RRR-alpha-tocopherol/d)
Number of subjects: 70
Study 11430960 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 149
Study 11430960 — intervention group
Group type: COMPARATOR
Intervention: Saline controls
Number of subjects: 149
Study 11430960 — intervention group
Group type: COMPARATOR
Intervention: Other tocolytic agents
Number of subjects: 149
Study 10211065 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical filter-based exposure equalization technique
Number of subjects: 533
Study 10211065 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 533
Study 8025301 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (r-IFN-alpha-2b) 6 MU tiw for 2 months followed by 3 MU for 7 months (Group A)
Number of subjects: 117
Study 8025301 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (r-IFN-alpha-2b) 6 MU tiw for 2 months followed by 1.5 MU for 7 months (Group B)
Number of subjects: 117
Study 8025301 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B) during the first two months at 6 MU
Number of subjects: 117
Study 8025301 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (3 MU)
Number of subjects: 117
Study 8025301 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (1.5 MU)
Number of subjects: 117
Study 2514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 150-200 mg/day
Number of subjects: 31
Study 2514653 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg/day
Number of subjects: 31
Study 4393354 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (5 to 1,280 mg orally)
Number of subjects: 16
Study 4393354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (5 to 1,280 mg orally)
Number of subjects: 16
Study 4393354 — intervention group
Group type: COMPARATOR
Intervention: Control period (no drug)
Number of subjects: 16
Study 30554237 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on influenza infection and vaccination (38 participants)
Number of subjects: 125
Study 30554237 — intervention group
Group type: COMPARATOR
Intervention: Control group (87 participants)
Number of subjects: 125
Study 30554237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (125 participants)
Number of subjects: 125
Study 30554237 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Workers who underwent vaccination
Number of subjects: 125
Study 29096156 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with ER-negative breast cancer
Number of subjects: 734
Study 29096156 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with premenopausal ER-positive tumours
Number of subjects: 734
Study 29096156 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients with premenopausal ER-positive tumours
Number of subjects: 734
Study 29096156 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients with postmenopausal ER-positive tumours
Number of subjects: 734
Study 29096156 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with postmenopausal ER-positive tumours
Number of subjects: 734
Study 25427411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dor fundoplication
Number of subjects: 62
Study 25427411 — intervention group
Group type: COMPARATOR
Intervention: Angle of His accentuation
Number of subjects: 62
Study 23253647 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and care strategy
Number of subjects: 3538
Study 23253647 — intervention group
Group type: COMPARATOR
Intervention: Education and environment strategies
Number of subjects: 3538
Study 21981909 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self-Management Support intervention (12 sessions, starting prior to surgery and continuing for approximately 9 weeks post-TKR)
Number of subjects: 0
Study 21981909 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study 18306243 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline (40mg/day)
Number of subjects: 196
Study 18306243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 14756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive trauma therapy for battered women with PTSD (CTT-BW)
Number of subjects: 125
Study 11177402 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine (dual therapy)
Number of subjects: 137
Study 11177402 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, didanosine, and lamivudine (triple therapy)
Number of subjects: 137
Study 11177402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 137
Study 9638980 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-risk group receiving CHOP chemotherapy
Number of subjects: 158
Study 9638980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients treated with low-dose CHOP
Number of subjects: 158
Study 9638980 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients treated with vincristine/prednisone
Number of subjects: 158
Study 9638980 — intervention group
Group type: COMPARATOR
Intervention: Normal-risk patients during chemotherapy
Number of subjects: 158
Study 8091999 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot antipsychotic medication during the initial 1-year period
Number of subjects: 0
Study 8091999 — intervention group
Group type: COMPARATOR
Intervention: Medication-free period
Number of subjects: 0
Study 8091999 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance antipsychotic medication
Number of subjects: 0
Study 8091999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low expressed emotion environment
Number of subjects: 0
Study 2734719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment (Rocgel)
Number of subjects: 10
Study 2734719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29727048 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation (PBM)
Number of subjects: 101
Study 29727048 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 101
Study 26424178 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI-GA (General Anaesthesia)
Number of subjects: 66
Study 26424178 — intervention group
Group type: COMPARATOR
Intervention: TAVI-S (Sedation)
Number of subjects: 66
Study 24206823 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttermilk (45 g/d)
Number of subjects: 34
Study 24206823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (45 g/d)
Number of subjects: 34
Study 22309805 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Number of subjects: 0
Study 22309805 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 0
Study 22309805 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor + Endothelin-1
Number of subjects: 0
Study 22309805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20668532 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood-high arousal
Number of subjects: 0
Study 20668532 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood-low arousal
Number of subjects: 0
Study 20668532 — intervention group
Group type: COMPARATOR
Intervention: Positive mood-low arousal
Number of subjects: 0
Study 20668532 — intervention group
Group type: COMPARATOR
Intervention: Negative mood-high arousal
Number of subjects: 0
Study 18538464 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotripsy
Number of subjects: 52
Study 18538464 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 16001993 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m2 I.V. on day 1 and cyclophosphamide 100 mg/m2 orally on days 1‐14 every 28‐day cycle
Number of subjects: 51
Study 16001993 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Number of subjects: 51
Study 16001993 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 35 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Number of subjects: 51